Hematology Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', 70124 Bari, Italy.
School of Medicine, University of Bari 'Aldo Moro', 70124 Bari, Italy.
Int J Mol Sci. 2023 Mar 2;24(5):4860. doi: 10.3390/ijms24054860.
Nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) is the most widely investigated inflammasome member whose overactivation can be a driver of several carcinomas. It is activated in response to different signals and plays an important role in metabolic disorders and inflammatory and autoimmune diseases. NLRP3 belongs to the pattern recognition receptors (PRRs) family, expressed in numerous immune cells, and it plays its primary function in myeloid cells. NLRP3 has a crucial role in myeloproliferative neoplasms (MPNs), considered to be the diseases best studied in the inflammasome context. The investigation of the NLRP3 inflammasome complex is a new horizon to explore, and inhibiting IL-1β or NLRP3 could be a helpful cancer-related therapeutic strategy to improve the existing protocols.
核苷酸结合寡聚化结构域样受体蛋白 3(NLRP3)是研究最为广泛的炎症小体成员之一,其过度激活可能是多种癌症的驱动因素。它可以响应不同的信号而被激活,并在代谢紊乱以及炎症和自身免疫性疾病中发挥重要作用。NLRP3 属于模式识别受体(PRRs)家族,表达于多种免疫细胞中,其主要功能在髓系细胞中发挥。NLRP3 在骨髓增生性肿瘤(MPNs)中具有关键作用,被认为是炎症小体背景下研究最为充分的疾病。对 NLRP3 炎症小体复合物的研究是一个新的探索领域,抑制白细胞介素 1β(IL-1β)或 NLRP3 可能是一种有助于癌症的治疗策略,以改善现有的方案。